Last reviewed · How we verify
Nitroglycerin Topical Product
Nitroglycerin Topical Product is a Small molecule drug developed by Deborah Heart and Lung Center. It is currently in Phase 2 development.
Nitroglycerin topical product is used to treat postoperative pain after endoscopic rubber band ligation, as per a randomized, double-blind, placebo-controlled study. The exact mechanism of action of nitroglycerin topical product is unknown.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Nitroglycerin Topical Product |
|---|---|
| Sponsor | Deborah Heart and Lung Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effect of Topically-applied Milrinone or Nitroglycerin on Internal Mammary Artery Free Flow (PHASE3)
- Nitroglycerin Ointment for Pain Relief After Endoscopic Hemorrhoid Band Ligation (PHASE4)
- Physiologic Effect of Topical Nitroglycerin on Microcirculation Capacity in Patients With Circulatory Shock.
- Efficacy and Safety of Propionibacterium Extract Gel Versus 0.4% Glyceryl Trinitrate Ointment in the Treatment of Chronic Anal Fissure: a Randomised Controlled Trial (PHASE4)
- Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon (PHASE2)
- Short Term Results of Platelet-rich Plasma in the Treatment of Chronic Anal Fissure (PHASE4)
- Clinical Trial Using Topically Applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (PHASE3)
- Radial Artery Dilation Study: The Effect of Topical Administration of Nitroglycerin and Lidocaine Versus Lidocaine Alone of the Radial Artery Diameter (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nitroglycerin Topical Product CI brief — competitive landscape report
- Nitroglycerin Topical Product updates RSS · CI watch RSS
- Deborah Heart and Lung Center portfolio CI
Frequently asked questions about Nitroglycerin Topical Product
What is Nitroglycerin Topical Product?
Who makes Nitroglycerin Topical Product?
What development phase is Nitroglycerin Topical Product in?
Related
- Manufacturer: Deborah Heart and Lung Center — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing